Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353 ·Status: COMPLETED ·Phase: PHASE3

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

NCT03712228 ·Status: COMPLETED ·Phase: PHASE2

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

NCT03845400 ·Status: COMPLETED

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

NCT05469789 ·Status: ACTIVE_NOT_RECRUITING

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00262288 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00261053 ·Status: COMPLETED ·Phase: PHASE2

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881 ·Status: RECRUITING ·Phase: PHASE3

A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis

NCT04861090 ·Status: COMPLETED

A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT06353971 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations

NCT00004694 ·Status: COMPLETED ·Phase: NA

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

NCT06990529 ·Status: RECRUITING ·Phase: PHASE2

Characterization of Rhythmicity Profiles of Bradykinin-mediated Angioedema Attacks Using a Tracking Smartphone Application.

NCT05304091 ·Status: WITHDRAWN

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

NCT04656418 ·Status: COMPLETED ·Phase: PHASE3

Role of Circulating Innate Lymphoid Cells in Allergic Disorders

NCT03069495 ·Status: TERMINATED

A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)

NCT01066598 ·Status: TERMINATED ·Phase: PHASE2

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

NCT04070326 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

NCT05528861 ·Status: TERMINATED ·Phase: PHASE2

A Survey of Lanadelumab in Participants With Hereditary Angioedema

NCT05397431 ·Status: ACTIVE_NOT_RECRUITING

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT06736262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

NCT03693625 ·Status: TERMINATED ·Phase: PHASE2

Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment

NCT01359384 ·Status: UNKNOWN

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

NCT07204938 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

NCT04206605 ·Status: COMPLETED ·Phase: PHASE3

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

NCT00216762 ·Status: TERMINATED ·Phase: PHASE1/PHASE2